WAVEMAN · COMPANY

DRUG · Bright Minds Biosciences Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

DRUG

Name: BRIGHT MINDS BIOSCIENCES INC. (DRUG) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

BRIGHT MINDS BIOSCIENCES INC.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001827401

SEC FILINGS☆ WATCH

INSIDER NET · 180D

-$9.8M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$9.8M over 180 days

below 84% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

69 funds added or opened last quarter

more than 53% of Pharma & Biotech

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

19.7% of shares outstanding short · 4.0 days to cover · settled 2026-07-31

more than 96% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

69 funds added or opened positions in the latest 13F quarter, of 102 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +75.3%

+75.3%12M

INSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows a net $9.8M sold by insiders over 180 days, 69 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, BRIGHT MINDS BIOSCIENCES INC. insiders sold a net $9.8M of stock across 13 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Cormorant Asset Management, LP

—

SELL

2026-04-28

109,331.0

$9.8M

Cormorant Asset Management, LP

—

BUY

2024-11-04

184,331.0

$4.0M

Cormorant Global Healthcare Master Fund, LP

—

BUY

2024-10-16

7,150.0

$171.8K

Cormorant Global Healthcare Master Fund, LP

—

BUY

2024-10-16

3,107.0

$78.4K

Cormorant Global Healthcare Master Fund, LP

—

BUY

2024-10-16

39,743.0

$922.8K

13 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 8 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Jupiter Topco LLC

1,349,107.0 sh

$94.8M

Cormorant Asset Management, LP

900,000.0 sh

$63.2M

BlackRock, Inc.

686,184.0 sh

$48.2M

Vivo Capital, LLC

557,172.0 sh

$39.1M

Vestal Point Capital, LP

545,000.0 sh

$38.3M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

AdvisorShares Psychedelics ETF

$920.4K POSITION · AS OF 2026-03-31

4.5%

Driehaus Micro Cap Growth Fund

$3.1M POSITION · AS OF 2026-03-31

0.7%

Eventide Healthcare & Life Sciences Fund

$9.5M POSITION · AS OF 2026-03-31

0.6%

Adara Smaller Companies Fund

$1.7M POSITION · AS OF 2026-02-28

0.2%

VANGUARD U.S. MOMENTUM FACTOR ETF

$1.9M POSITION · AS OF 2026-02-28

0.1%

BlackRock Health Sciences Opportunities Portfolio

$8.0M POSITION · AS OF 2026-02-27

0.1%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2024-09	2023-09	2022-09	2021-09
NET INCOME	$-2.8M	$-7.4M	$-15.0M	$-8.7M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE